Baseline characteristics | Without vertebral fractures (n = 234) | With vertebral fractures (n = 41) | p-value |
---|---|---|---|
Age, mean ± SD years | 53 (13) | 60 (11) | 0.001 |
Female gender, no. (%) | 159 (68) | 26 (63) | 0.568 |
Symptom duration, median (IQR) weeks | 24 (14-50) | 23 (15-49) | 0.673 |
DAS, mean ± SD | 4.4 (0.9) | 4.2 (0.7) | 0.069 |
HAQ, mean ± SD | 1.3 (0.6) | 1.4 (0.7) | 0.594 |
BMI, mean ± SD | 26 (4) | 25 (4) | 0.545 |
ESR, mean ± SD | 36 (19-56) | 44 (26-57) | 0.098 |
CRP, mean ± SD | 20 (9-52) | 30 (12-51) | 0.298 |
RF positive, no. (%) | 152 (65) | 29 (71) | 0.472 |
ACPA positive, no. (%) | 148 (64) | 24 (59) | 0.543 |
Smoking yes, no (%) | 80 (34) | 21 (51) | 0.037 |
Treatment strategy, no. (%) | 0.833 | ||
Sequential monotherapy | 67 (28.6) | 9 (22) | |
Step-up therapy | 48 (20.5) | 10 (24.4) | |
Initial combo with prednisone | 55 (23.5) | 10 (24.4) | |
Initial combo with infliximab | 64 (27.4) | 12 (29.3) |